26
|
Arrieta O, Maldonado F, Ramírez-Tirado L, Barron F, Campos-Salgado Y, Blake M, Cardona A, De La Garza J. MA08.02 Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High-Risk Lung Cancer Patients: EGFR and ALK Mutations. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.377] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Zatarain-Barrón Z, Barron F, Cardona A, Cruz-Rico G, Arrieta O, Flores-Veles K, Espenschied C, Raymond V, Lanman R, Vargas C. P1.09-21 Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Cardona A, Arrieta O, Rojas L, Zatarain-Barrón Z, Ricaurte L, Ruiz-Patiño A, Martin C, Carranza H, Vargas C, Otero J, Corrales L. P3.01-11 Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Karachaliou N, Chaib I, Bracht J, Filipska M, Drozdowskyj A, Cardona A, Vergnenegre A, Sánchez-Torres J, Provencio M, De Marinis F, Carcereny E, Reguart N, García Campelo R, Santarpia M, Viteri S, Bivona T, Rosell R. P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
30
|
Gonzalez-Ling A, Maldonado F, Salinas Padilla M, Arguelles M, Ramírez-Tirado L, Zatarain-Barrón Z, Barron F, Cabrera-Miranda L, Flores D, Cardona A, Arrieta O. P1.01-03 Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Teixidó C, Pare L, Aguado C, Lopez S, Giménez-Capitán A, Cardona A, Cabrera C, Castillo S, Garzón M, Mayo C, Sullivan I, Muñoz S, Castellano G, Jares P, Prat A, Molina-Vila M, Reguart N. P3.04-16 A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Cardona A, Ruiz-Patiño A, Castro C, Rojas L, Arrieta O, Zatarain-Barrón Z, Carranza H, Vargas C, Otero J, Corrales L, Martin C, Rosell R. P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Cabrera-Miranda L, Barron F, Zatarain-Barrón Z, Ramírez-Tirado L, Salinas Padilla M, Corona-Cruz J, Cardona A, Arguelles M, Maldonado F, Blake M, Jiménez-Fuentes E, Aren O, Arrieta O. MA25.10 Complete Response by PET-CT After Radical Treatment in Oligometastatic Non-Small Cell Lung Cancer Predicts Longer Survival. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
34
|
Garcia – Roman S, Codony-Servat J, Molina-Vila M, Bertran-Alamillo J, Giménez-Capitán A, Viteri S, Cardona A, Rodríguez-Abreu D, Cobo Dols M, Reguart N, Karachaliou N, D'Hondt E, Rosell R. P1.13-01 Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Cruz-Rico G, Popa Navarro X, Avilés-Salas A, Flores-Vélez K, Cardona A, Ramírez-Tirado L, Vergara E, Barron F, Cabrera-Miranda L, Arrieta O. P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Cardona A, Prada-Arismendy J, Castillo E, Arroyave J. The reduction of the expression of B-catenin and c-Myc is related to a better outcome in patients with AML. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Ruiz-Patiño A, Castro C, Ricaurte L, Cardona A, Rojas L, Zatarain-Barrón Z, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodríguez J, Avila J, Bravo M, Pino L, Rosell R, Arrieta O. P02 EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
38
|
Zatarain-Barrón Z, Barrón F, Cardona A, Cruz-Rico G, Flores-Veles K, Espenschied C, Raymond V, Lanman R, Vargas C, Arrieta O. PD.2.05 Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Román-Gonzalez A, Cardona A, Gutiérrez J, Palacio A. Manejo de pacientes diabéticos hospitalizados. REVISTA DE LA FACULTAD DE MEDICINA 2018. [DOI: 10.15446/revfacmed.v66n3.61890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
La diabetes es una enfermedad con importante prevalencia en todo el mundo. Se calcula que cerca de 415 millones de personas la padecen en la actualidad y que para el año 2040 esta cifra aumentará poco más del 50%. Debido a esto, se estima que gran parte de los ingresos por urgencias serán de pacientes diabéticos o sujetos a los cuales esta patología se les diagnosticará en dicha hospitalización; esta situación hace necesario conocer los lineamientos y las recomendaciones de las guías para el manejo intrahospitalario de los pacientes con hiperglucemia.El pilar fundamental del manejo hospitalario de diabetes es la monitorización intensiva, junto con la educación al paciente y la administración de insulina. El control glicémico es clave debido a que disminuye complicaciones intrahospitalarias. Cabe resaltar que el control estricto puede llevar a hipoglucemias, por lo que los episodios deben ser debidamente documentados y su causa corregida de inmediato.
Collapse
|
40
|
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol 2018; 20:1529-1537. [PMID: 29737461 DOI: 10.1007/s12094-018-1883-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 04/23/2018] [Indexed: 11/29/2022]
Abstract
PURPOSE We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. PATIENTS AND METHODS We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy. RESULTS OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor. CONCLUSION In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
Collapse
|
41
|
Arrieta O, Orozco-Morales M, Cardona A, Avilés A, Hernandez-Pedro N, Cabrera-Miranda L, Soca-Chafre G, Barrios P, Cruz-Rico G. P1.07-041 CD47 Expression and Prognosis in a Cohort of Patients with Lung Adenocarcinoma (NSCLC). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Cardona A, Arrieta O, Oblitas G, Rojas L, Zatarain-Barron Z, Corrales L, Martin C, Rodriguez J, Archila P, Ruiz-Patiño A, Pérez M, González L, Chirinos L, Carranza H, Vargas C, Rosell R. P3.02-063 EGFR Exon 20 Insertions in Lung Adenocarcinomas: Molecular and Clinicopathologic Characteristics Among Hispanics (Geno1.2-CLICaP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
43
|
Cardona A, Martínez S, Arrieta O, Serna A, Barrios R, Garzón J, Navarrete C, Balaguera A, Reyes O, Galvis D, Zatarain-Barron Z, Rojas L. P3.08-005 Hereditary Familial Overlap Syndrome with Multiple Synchronous Lung Tumors. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
44
|
Cardona A, Arrieta O, Rojas L, Zatarain-Barron Z, Corrales L, Martin C, Rodriguez J, Rodriguez J, Archila P, Ruiz-Patiño A, Rosell R. P1.02-055 Genotyping Squamous Cell Lung Carcinoma Among Hispanics (Geno1.1-CLICaP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.788] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Cardona A, Arrieta O, Rojas L, Zatarain-Barron Z, Corrales L, Martin C, Rodriguez J, Rodriguez J, Archila P, Ruiz-Patiño A, Rosell R. MA 01.02 Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers Versus Heavy Smokers. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
46
|
Martín C, Cardona A, Arrieta O, Castillo-Fernandez O, Oblitas G, Corrales L, Lupinacci L, Pérez M, Rojas L, González L, Chirinos L, Ortíz C, Lema M, Vargas C, Puparelli C, Carranza H, Otero J, Ramirez-Tirado L. P1.01-019 ALK+ Non-Small Cell Lung Cancer Treated with First Line Crizotinib: Patient Characteristics, Treatment Patterns, and Survival. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Cardona A, Arrieta O, Rojas L, Corrales L, Wills B, Oblitas G, Bacon L, Martin C, Cuello M, Mas L, Vargas C, Carranza H, Otero J, Pérez M, González L, Chirinos L, Rosell R. P1.09-013 Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma Among Hispanics (MeSO-CLICaP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Karachaliou N, Cardona A, Cao MG, Giménez-Capitán A, Drozdowskyj A, Aldeguer E, López-Vivanco G, Sánchez-Torres J, De Los Llanos Gil M, Molina-Vila M, Rosell R. P2.02-034 PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
49
|
Mazieres J, Novello S, De Castro J, Migliorino M, Helland Å, Dziadziuszko R, Griesinger F, Wolf J, Zeaiter A, Cardona A, Balas B, Karagiannis T, Chlistalla M, Smoljanovic V, Oh I. P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.667] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
50
|
Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino M, Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeiter A, Cardona A, Balas B, Johannsdottir H, Das-Gupta A, Wolf J. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.058] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|